Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01626573 · ClinicalTrials.gov registry record · Phase 2
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT01626573 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 106 participants.
The verdict
NCT01626573, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
Interventions
- DRUG Itacitinib
- DRUG Itacitinib Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01626573
The ClinicalTrials.gov registry entry for NCT01626573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itacitinib is the first listed.
NCT01626573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01626573 about?
NCT01626573 is a clinical study titled "A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis". This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
What is the current status of trial NCT01626573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2012-03. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01626573?
The interventions under investigation include: Itacitinib (DRUG), Itacitinib Placebo (DRUG).
Who is sponsoring clinical trial NCT01626573?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.